Clinical trials
Cervical Carcinoma clinical trials
Below are recruiting cervical carcinoma clinical trials, each written for real people, not researchers. We’re tracking 104 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06052033Recruiting
Light therapy vs. laser for persistent cervical changes with HPV
This study compares two treatments—photodynamic therapy using a special light-activated cream and a CO2 laser—to see which works better for clearing low-grade cervical changes caused by a long-lasting high-risk HPV infection. The goal is to find a safe, effective option for women who have had this condition for over a year.
Wenzhou, ZhejiangAges 18–65 - NCT07223424RecruitingPhase 2
Patient preference study: shot vs infusion for immunotherapy
This study compares two ways to take immunotherapy drugs (nivolumab or pembrolizumab): as a shot under the skin (subcutaneous) versus an infusion into a vein (intravenous). It looks at which method patients prefer and is for people with certain advanced cancers where these drugs are already approved.
Pittsburgh, PennsylvaniaAges 18 years+ - NCT05107674RecruitingPhase 1
Early drug study for advanced cancers that have limited options
This Phase 1 study tests NX-1607 in adults with advanced cancers that are hard to treat with standard care. It focuses on safety and early signs of how well the drug may work in specific cancer types.
Duarte, CaliforniaAges 18 years+ - NCT07400536RecruitingPhase 3
Cadonilimab plus chemo and radiation for advanced cervical cancer
This trial tests a new immunotherapy drug, cadonilimab, combined with standard chemotherapy followed by chemoradiation for locally advanced cervical cancer. The goal is to see if this combination works better than current treatments.
Wuhan, HubeiAges 18–70 - NCT06810739Recruiting
Women's Screening and Self-Testing Program (PROMETA)
This study tests a self-screening program for cervical cancer among women who are already receiving HIV care. It aims to make screening easier and more accessible.
MaputoAges 25–49 - NCT05799274RecruitingPhase 1
Safety study of a new PET imaging drug for cancers
This Phase 1 study tests how safe RAD301 is and how it behaves in the body when given for PET imaging in healthy volunteers and people with certain cancers. It may help doctors learn whether this imaging drug can clearly show cancer areas and be tolerated well.
Princeton, New JerseyAges 18 years+ - NCT05366478RecruitingPhase 1
LM103 for advanced solid tumors using donated immune cells
This Phase 1 study tests LM103 to treat advanced cancers that are not responding to standard treatment. It also looks at whether enough tumor tissue can be collected for immune cell testing, and focuses on safety at first.
TianjinAges 18 years+ - NCT05829629RecruitingPhase 1
Test of an HPV vaccine-like treatment for HPV16 in women
This Phase 1 study tests FluBHPVE6E7, a new treatment designed to help the immune system respond to HPV16. It mainly checks safety and the best dose, and may help your body clear or control HPV over time.
BratislavaAges 18–49 - NCT06230549Recruiting
Adaptive radiotherapy for gynecological tumors
This trial tests a personalized radiation therapy approach for gynecological tumors. It aims to improve treatment by adapting the radiation plan based on changes in the tumor and nearby organs during your therapy course.
Essen, Germany / NRWAges 18 years+ - NCT06265025RecruitingPhase 1/Phase 2
GM103 injection for advanced solid tumors that can't be removed
This trial tests an experimental drug called GM103 that is injected directly into tumors. It is for people with advanced solid tumors that have not responded to other treatments and cannot be surgically removed.
Goyang-si, Gyeonggi-doAges 18 years+ - NCT06398938Recruiting
High dose rate radiation therapy for cervical cancer
This trial tests a faster, high-dose radiation treatment for cervical cancer that is given directly into the uterus. It aims to see if this approach is safe and effective for women with certain stages of the disease.
RomeAges 18 years+ - NCT06800612Recruiting
Cancer drug therapy study for gynecologic or breast cancers
This study looks at how well different cancer drugs work for women with breast or gynecologic cancers. Researchers will review medical records to see how patients responded to treatment over time. If you have been treated for breast or gynecologic cancer since 2010, you may be eligible.
BolognaAges 18 years+ - NCT07336147RecruitingPhase 2
Immunotherapy, chemo, and radiation for cervical cancer
This study tests a combination of immunotherapy (dostarlimab), chemotherapy (cisplatin and etoposide), and radiation to treat small cell neuroendocrine cervical cancer. The goal is to see if this approach works better and is safe for people who haven't had treatment yet.
Taoyuan, TaiwanAges 20–70 - NCT06400472RecruitingPhase 1
Study of LY4170156 for advanced solid tumors
This study tests a new drug called LY4170156 for people with certain advanced solid tumors. It aims to see if the drug is safe and how well it works.
Scottsdale, ArizonaAges 18 years+ - NCT05086692RecruitingPhase 1/Phase 2
Beta-only IL-2 therapy for advanced solid tumors
This Phase 1/2 study tests a beta-only version of IL-2, an immune-stimulating treatment, to shrink or control advanced or metastatic solid tumors. It’s mainly designed to check safety and to see if it can help patients by improving tumor response.
San Diego, CaliforniaAges 18 years+ - NCT07557225Recruiting
New PET Scan for Detecting Multiple Cancer Types
This study tests a new type of PET scan (a specialized imaging test) that may better detect certain cancers by looking for a specific marker found on many tumor types. The scan uses a new tracer called 18F-T2 to help doctors see cancer more clearly.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07169734RecruitingPhase 1/Phase 2
ALE.P03 for advanced CLDN1-positive solid tumors
This trial tests a new drug, ALE.P03, for people with advanced or metastatic solid tumors that have a certain protein (CLDN1). The drug is given alone (monotherapy) to see if it can shrink tumors or slow their growth.
Phoenix, ArizonaAges 18 years+ - NCT04977453RecruitingPhase 1/Phase 2
Study drug GI-101 alone or with immune or blood-pressure meds
This early-phase study tests GI-101 in people with advanced solid cancers. It may be given alone or combined with pembrolizumab or lenvatinib to see how safe it is and whether it can shrink tumors.
New York, New YorkAges 18 years+ - NCT06799637RecruitingPhase 1/Phase 2
Study of XNW28012 for advanced solid tumors
This trial tests a new drug called XNW28012 for people with advanced solid tumors that have not responded to or caused side effects from standard treatments. It aims to see if the drug can shrink tumors or slow their growth.
Hefei, AnhuiAges 18 years+ - NCT06814496RecruitingPhase 1/Phase 2
Radiation and immunotherapy combo for DLL3-positive cancers
This trial combines radiation with an immunotherapy drug called tarlatamab to treat cancers that make a protein called DLL3. The goal is to see if this combination works better than either treatment alone for people with certain types of lung cancer and other tumors that have not responded to prior therapy.
Tucson, ArizonaAges 18–99 - NCT05197881Recruiting
Daily adaptive radiation for newly diagnosed cervical cancer
This study tests a radiation plan that is adjusted day by day to better match your cervix and surrounding tissues during treatment. It’s for newly diagnosed, advanced cervical cancer patients who will receive standard pelvic radiation and chemotherapy.
Burmingham, AlabamaAges 18 years+ - NCT05952947RecruitingPhase 1
Study drug for HPV18-positive solid tumors with a specific immune marker
This Phase 1 trial tests HRYZ-T101 injection for people whose solid cancer is HPV18-positive and who have the HLA-DRB1*0901 immune marker. It is meant for people whose cancer has returned or spread and who have few or no effective treatment options.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06677190RecruitingPhase 2
Belzutifan for Recurrent Clear Cell Gynecologic Cancer
This study tests a daily pill called belzutifan for people with a rare type of gynecologic cancer (clear cell carcinoma) that has come back or not gone away after standard treatments. The drug works by targeting a protein that helps tumors grow when oxygen levels are low.
Boston, MassachusettsAges 18 years+ - NCT06293898RecruitingPhase 1
Study of BL-M07D1 for HER2-positive solid tumors
This trial tests a new drug, BL-M07D1, for people with advanced solid tumors that have a protein called HER2. It is for patients who have already tried at least two other standard treatments.
Birmingham, AlabamaAges 18 years+
Hear when a new Cervical Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for cervical carcinoma?
- Yes. Clin2 currently lists 104 recruiting cervical carcinoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a cervical carcinoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a cervical carcinoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.